Research Analysts Set Expectations for LXEO Q1 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Lexeo Therapeutics in a research report issued on Monday, March 24th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earnings per share of ($0.80) for the quarter. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.79) EPS and Q4 2025 earnings at ($0.79) EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.09.

LXEO has been the subject of several other reports. Chardan Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research note on Wednesday. Leerink Partners lowered their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Monday. Finally, Royal Bank of Canada cut their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Lexeo Therapeutics has an average rating of “Buy” and an average price target of $22.80.

Lexeo Therapeutics Price Performance

LXEO stock opened at $4.11 on Wednesday. The firm has a 50 day moving average of $4.07 and a 200-day moving average of $6.63. The company has a market cap of $135.90 million, a price-to-earnings ratio of -1.30 and a beta of 3.85. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 12-month low of $2.32 and a 12-month high of $19.50.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Allostery Investments LP purchased a new stake in Lexeo Therapeutics in the fourth quarter valued at approximately $33,000. BNP Paribas Financial Markets boosted its holdings in shares of Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Lexeo Therapeutics during the 4th quarter valued at $46,000. JPMorgan Chase & Co. increased its holdings in shares of Lexeo Therapeutics by 135.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after buying an additional 5,915 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new stake in shares of Lexeo Therapeutics during the 4th quarter worth $69,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.